Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

99 years and younger
All genders
The primary objective of this study is to assess whether preoperative hemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of patients with high risk de-differentiated liposarcoma DDLPS) and leiomyosarcoma (LMS) as measured by disease-free survival.
Learn More

UPCC 20522 A Phase 1 Open-Label Study of Patritumab Deruxtecan in Combination with Osimertinib in Subjects with Locally Advanced or metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

99 years and younger
All genders
This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety.
Learn More

UPCC 28822: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations (NePtune)

99 years and younger
All genders
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic BRCA1/2 gene mutation. We would like …
Learn More

VBX 22-06

99 years and younger
All genders
The purpose of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease. Patients are adults presenting with symptomatic, complex iliac occlusive disease.
Learn More

UPCC 45423 A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Brutons Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

99 years and younger
All genders
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies. We would like to rely on WCG IRB as the IRB of record for this study.
Learn More

BMS 1015

99 years and younger
All genders
This protocol will assess the safety and tolerability of BMS 986278 in patients with PPF. It will involve PEs, safety labs, clinical labs, pulmonary tests, EKGs, HRCTs, vital signs, and 6MWTs.
Learn More

ORIGIN

99 years and younger
All genders
Study is enrolling IgAN patients who continue to have persistent proteinuria despite being on RAAS inhibitors for at least 12 weeks. The study intervention is subcutaneous atacicept given once a week. Interested subjects will be taking study drug for up to 96 weeks (36 weeks blinded + 60 weeks open …
Learn More

UPCC 40423 A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

99 years and younger
All genders
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD). We would like to rely on NMDP IRB as the IRB of record for this study.
Learn More

UPCC 32423 An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, A CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Direc

99 years and younger
All genders
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy for the treatment of relapsed or refractory large B-cell lymphoma.
Learn More

UPCC 47423:A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

99 years and younger
All genders
TrAVeRse is a multicenter, open-label, randomized, Phase II study of AVR in treatment naive MCL participants. The primary objective is to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at end of AVR induction will be randomized …
Learn More
631 - 640 of 930